colorectal lesions
Conditions
Interventions
Randomized allocation of the observation method used for the initial observation
In the standard treatment group (WLI group), on Visit 1 (day 0), Olympus Medical Systems Co., Ltd.'s new colonoscopy sy
Sponsors
Saito Yutaka
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet all of the inclusion criteria 1 to 3 below 1)Patients aged between 40 and 80 at the time of informed consent 2)Patients scheduled for colonoscopy for any of the following: 1.Screening 2.Surveillance after endoscopic treatment (removal of all adenomas) 3.Examination for positive fecal occcult blood test 4.Examination of abdominal symptoms (melena, bloody stool, other symptoms) 3)Patients who have given written informed consent to participate in the study
Exclusion criteria
Exclusion criteria: Patients who do not correspond to any of the following1to7 1)Patients with a history of colorectal surgery (excluding appendectomy) 2)Patients with colonic polyposis 3)Patients with inflammatory bowel disease 4)Patients with known colorectal polyps 5)Women who are pregnant or breastfeeding 6)Patients participating in an interventional study on endoscopy other than this study 7)Patients who are judged to be inappropriate for this study by the attending physician or the examining physician, including underlying diseases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean adenoma per procedure | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Adenoma detection rate(ADR) 2)Advanced ADR 3)Polyp detection rate(PDR) 4)Flat polyp detection rate(FDR) 5)Depressed lesion detection rate (DDR) 6)Average number of polyps found per examination 7)Sessile serrated lesion detection rate(SDR) 8)Average number of SSLs found per inspection 9)MAP/ADR by doctor skill level 10)MAP/ADR by gross lesion type 11)Adverse event frequency | — |
Contacts
Public ContactNaoya Toyoshima
National Cancer Center Hospital
Outcome results
None listed